Dissecting the DNA binding landscape and gene regulatory network of p63 and p53
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Germany
- Max Planck Institute for Molecular Genetics, Germany
- Queen's University Belfast, United Kingdom
Abstract
The transcription factor p53 is the best-known tumor suppressor, but its sibling p63 is a master regulator of epidermis development and a key oncogenic driver in squamous cell carcinomas (SCC). Despite multiple gene expression studies becoming available, the limited overlap of reported p63-dependent genes has made it difficult to decipher the p63 gene regulatory network. Particularly, analyses of p63 response elements differed substantially among the studies. To address this intricate data situation, we provide an integrated resource that enables assessing the p63-dependent regulation of any human gene of interest. We use a novel iterative de novo motif search approach in conjunction with extensive ChIP-seq data to achieve a precise global distinction between p53 and p63 binding sites, recognition motifs, and potential co-factors. We integrate these data with enhancer:gene associations to predict p63 target genes and identify those that are commonly de-regulated in SCC representing candidates for prognosis and therapeutic interventions.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
-
Transcription factor p63 bookmarks and regulates dynamic enhancers during epidermal differentiationNCBI Gene Expression Omnibus, GSE59824.
-
p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell modelNCBI Gene Expression Omnibus, GSE43111.
-
Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional programNCBI Gene Expression Omnibus, GSE60814.
-
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomasNCBI Gene Expression Omnibus, GSE46837.
-
ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell CarcinomasNCBI Gene Expression Omnibus, GSE111619.
-
p63 regulates an adhesion programme and cell survival in epithelial cellsNCBI Gene Expression Omnibus, GSE20286.
-
ΔNp63α represses anti-proliferative genes via H2A.Z depositionNCBI Gene Expression Omnibus, GSE40462.
-
Control of p53-dependent transcription and enhancer activity by the p53 family member p63NCBI Gene Expression Omnibus, GSE111009.
-
p63 establishes epithelial enhancers at critical craniofacial development genesNCBI Gene Expression Omnibus, GSE126397.
-
TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal AdenocarcinomaNCBI Gene Expression Omnibus, GSE115462.
-
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomasNCBI Gene Expression Omnibus, GSE47058.
Article and author information
Author details
Funding
Deutsche Forschungsgemeinschaft (FI 1993/2-1)
- Martin Fischer
Bundesministerium für Bildung und Forschung (031L016D)
- Steve Hoffmann
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2020, Riege et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,552
- views
-
- 394
- downloads
-
- 34
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Dissecting the DNA binding landscape and gene regulatory network of p63 and p53
eLife 9:e63266.
https://doi.org/10.7554/eLife.63266
Further reading
-
- Chromosomes and Gene Expression
- Microbiology and Infectious Disease
Candida glabrata can thrive inside macrophages and tolerate high levels of azole antifungals. These innate abilities render infections by this human pathogen a clinical challenge. How C. glabrata reacts inside macrophages and what is the molecular basis of its drug tolerance are not well understood. Here, we mapped genome-wide RNA polymerase II (RNAPII) occupancy in C. glabrata to delineate its transcriptional responses during macrophage infection in high temporal resolution. RNAPII profiles revealed dynamic C. glabrata responses to macrophages with genes of specialized pathways activated chronologically at different times of infection. We identified an uncharacterized transcription factor (CgXbp1) important for the chronological macrophage response, survival in macrophages, and virulence. Genome-wide mapping of CgXbp1 direct targets further revealed its multi-faceted functions, regulating not only virulence-related genes but also genes associated with drug resistance. Finally, we showed that CgXbp1 indeed also affects fluconazole resistance. Overall, this work presents a powerful approach for examining host-pathogen interaction and uncovers a novel transcription factor important for C. glabrata’s survival in macrophages and drug tolerance.
-
- Chromosomes and Gene Expression
- Neuroscience
Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.
